Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

HLX3901

Phase 1Small molecule

Shanghai Henlius Biotech

HLX3901 is one of 7 small molecule programs targeting SCLC. It is currently in Phase 1.

1

Indications

1

Total Trials

1

Active Trials

6

Competitors

Pipeline

Status by Indication[3][1]

Indication

SCLCRecruiting

SCLCPhase 1

Recruiting

Competition

Competitive Landscape

7 competitors in SCLC

#DrugCompanyPhaseTrials

Vepesid

Platinum

Bristol-Myers Squibb

Tecentriq

Serplulimab

Shanghai Henlius Biotech

Paraplatin

ZL-1310

ZZai Lab (Shanghai) Co., Ltd.

HLX3901

Shanghai Henlius Biotech

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 1Recruiting

SCLC

NCT07416695

Clinical

Trials by Indication[1]

SCLC1 trial

A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 (DLL3 × DLL3 × CD3 × CD28 Tetra-specific Antibody) in Patients With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma

Recruiting· Shanghai Henlius Biotech logo

Shanghai Henlius Biotech·Phase 1·NCT07416695·138 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for HLX3901. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HLX3901 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HLX3901. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Henlius Biotech company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Shanghai Henlius Biotech

Related News